Update 6-5-2017 Stephen Jackson, beat cancer – Keytruda

I have felt it’s been time for an update for a while so I’ll try to do one how‘s that. First off I would like to thank all those who have been keeping up with my progress in and out of the hospital, and as well as understanding this heart condition I have been putting myself through. You know there is a lot you don’t understand when you are sick. One thing is you can get heart congestion, which is what I got not knowing how, but still getting it. I was eating and I should not have been. I was...
More

Should the Schedule Change on Gabapentin?

The number of prescriptions being written for gabapentin -- typically used to treat seizures and painful nerve diseases -- is at an all-time high.1 According to a report by IMS Health, 57 million prescriptions for gabapentin were written in the United States in 2015, a 42% increase since 2011. Gabapentin is a medication that is structurally related to the inhibitory neurotransmitter GABA. It does not bind to the GABA receptors but instead modulates the release of excitatory neurotransmitters, w...
More

Gabapentin for Alcohol Use Disorder: A Promising Outlook

View all articles Alexander Kantorovich, PharmD, BCPS Alexander Kantorovich, PharmD, BCPS Alexander Kantorovich, PharmD, BCPS, is a Clinical Assistant Professor of Pharmacy Practice at Chicago State University College of Pharmacy and Clinical Pharmacy Specialist in the area of Internal Medicine at Advocate Christ Medical Center in Oak Lawn, Illinois. Dr. Kantorovich earned his Associate of Science degree with an emphasis in chemistry from William Rainey Harper College in 2008 and received his D...
More

Story image for keytruda hodgkin lymphoma from Zacks.com

Application (sBLA) – the second this week – for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA. This time, the company is looking to expand the label for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy. Merck’s shares are up 15% this year comparing favorably with a decline of 8.1% for the Zacks classified Large-Cap Pharma industry backed by consistently strong earnings res...
More

Story image for keytruda hodgkin lymphoma from Zacks.com

Application (sBLA) – the second this week – for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA. This time, the company is looking to expand the label for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy. Merck’s shares are up 15% this year comparing favorably with a decline of 8.1% for the Zacks classified Large-Cap Pharma industry backed by consistently strong earnings res...
More

FDA Approves New Drug for Hodgkin Lymphoma

On March 14, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for the treatment of some patients with classical Hodgkin lymphoma (cHL). The drug is approved for the treatment of both adult and pediatric patients with refractory cHL, or patients whose disease has relapsed after three or more lines of therapy. The FDA's action makes pembrolizumab the first immune checkpoint inhibitor to be approved for the treatment of children with cancer. The drug has previously been ap...
More

MSD’s Keytruda closer to classical Hodgkin Lymphoma nod

MSD’s anti-PD-1 therapy Keytruda has taken a giant leap towards being approved in Europe for the treatment of classical Hodgkin Lymphoma (cHL). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed expanding the list of approved uses for the drug to include relapsed or refractory cHL in adults who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV. http://www.pharmatimes.c...
More

Keytruda Proves Effectiveness with Mesothelioma

Immunotherapy drug pembrolizumab (Keytruda) continues to show ground-breaking effectiveness in the treatment of malignant pleural mesothelioma, according to the latest published study. Mesothelioma specialist Dr. Evan Alley detailed the results earlier this month in The Lancet Oncology. Alley, chief of hematology and medical oncology at Penn Presbyterian Medical Center, believes pembrolizumab could become an accepted second-line treatment for pleural mesothelioma. Pembrolizumab is marketed as Ke...
More

Woman’s brain tumour shrunk by Keytruda

  Not long ago Pamela Jones would have been told to get her affairs in order and sent home to die. Instead she has a future and is looking forward to seeing her daughter graduate and retiring and travelling with her husband. The 54-year-old is one of 223 New Zealanders who received the immunotherapy drug Keytruda in the first five months it was funded by Pharmac. Four years ago doctors found melanoma deposits when the Auckland woman had a mole cut out of her back. She had surgery to have it...
More